Results: 11/34 ALS subjects randomized ((intention-totreat
(ITT)) to Ibudilast compared with 2/17 subjects
randomized to placebo (p ¼ 0.1117) showed no progression
as assessed by NCE analysis during DB/OLE epochs
whereas 10/34 ALS subjects randomized (ITT) to
Ibudilast compared with 3/17 subjects randomized to
placebo (p ¼ 0.3638) showed no progression as assessed
by responder analysis during DB epoch. Subjects (ITT)
who showed no progression on 6 or 12 months Ibudilast
showed improved survival (p ¼ 0.0010) in the 30 months
post ibudilast treatment. Subjects who completed 6 or 12
months ibuidlast treatment ( per-protocol (PP) ) showed
improved survival (p ¼ 0.0025) in the 30 months post
Ibudilast treatment.
takarazimaniiku
>>8047
アブスト出てますよ。
Results: 11/34 ALS subjects randomized ((intention-totreat
(ITT)) to Ibudilast compared with 2/17 subjects
randomized to placebo (p ¼ 0.1117) showed no progression
as assessed by NCE analysis during DB/OLE epochs
whereas 10/34 ALS subjects randomized (ITT) to
Ibudilast compared with 3/17 subjects randomized to
placebo (p ¼ 0.3638) showed no progression as assessed
by responder analysis during DB epoch. Subjects (ITT)
who showed no progression on 6 or 12 months Ibudilast
showed improved survival (p ¼ 0.0010) in the 30 months
post ibudilast treatment. Subjects who completed 6 or 12
months ibuidlast treatment ( per-protocol (PP) ) showed
improved survival (p ¼ 0.0025) in the 30 months post
Ibudilast treatment.